Zimmermann Heiko, Shirley Stephen G, Zimmermann Ulrich
Lehrstuhl für Biotechnologie, Biozentrum, Universität Würzburg, Am Hubland, D-97074 Würzburg, Germany.
Curr Diab Rep. 2007 Aug;7(4):314-20. doi: 10.1007/s11892-007-0051-1.
Replacing dysfunctional endocrine tissues (eg, islets) with healthy, nonautologous material protected against the immune defense of the patient could soon become a reality. Recent advances have resulted in the development of alginate-based microcapsules that meet the demands of biocompatibility, long-term integrity, and function. Focus on the development of good manufacturing practice-conforming microfluidic chip technology for generation of immunoisolated transplants and on cryopreservation technology will bring the cell-based therapy to the market and clinics.
用能够抵御患者免疫防御的健康、非自体材料替代功能失调的内分泌组织(如胰岛)可能很快成为现实。最近的进展促成了符合生物相容性、长期完整性和功能要求的基于藻酸盐的微胶囊的开发。专注于开发符合良好生产规范的用于生成免疫隔离移植体的微流控芯片技术以及冷冻保存技术,将使基于细胞的疗法推向市场和临床。